BR112013028536A2 - variantes de albumina - Google Patents

variantes de albumina

Info

Publication number
BR112013028536A2
BR112013028536A2 BR112013028536A BR112013028536A BR112013028536A2 BR 112013028536 A2 BR112013028536 A2 BR 112013028536A2 BR 112013028536 A BR112013028536 A BR 112013028536A BR 112013028536 A BR112013028536 A BR 112013028536A BR 112013028536 A2 BR112013028536 A2 BR 112013028536A2
Authority
BR
Brazil
Prior art keywords
albumin
variants
albumin variants
relates
origin
Prior art date
Application number
BR112013028536A
Other languages
English (en)
Inventor
Andrew Plumridge
Bjorn Dalhus
Esben Peter Friis
Inger Sandlie
Jan Terje Andersen
Jason Cameron
Karen Delahay
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of BR112013028536A2 publication Critical patent/BR112013028536A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

variantes de albumina a invenção refere-se às variantes de uma albumina de origem tendo meia vida plasmática alterada, em comparação com a albumina de origem. a invenção também diz respeito a polipeptídeos de fusão e conjugados compreendendo a referida variante de albumina.
BR112013028536A 2011-05-05 2012-05-04 variantes de albumina BR112013028536A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11164991 2011-05-05
EP11185064 2011-10-13
EP12160007 2012-03-16
PCT/EP2012/058206 WO2012150319A1 (en) 2011-05-05 2012-05-04 Albumin variants

Publications (1)

Publication Number Publication Date
BR112013028536A2 true BR112013028536A2 (pt) 2016-11-29

Family

ID=46027974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028536A BR112013028536A2 (pt) 2011-05-05 2012-05-04 variantes de albumina

Country Status (14)

Country Link
US (3) US8822417B2 (pt)
EP (1) EP2705051A1 (pt)
JP (1) JP6430828B2 (pt)
KR (1) KR20140027307A (pt)
CN (2) CN110272484A (pt)
AU (2) AU2012251583B2 (pt)
BR (1) BR112013028536A2 (pt)
CA (1) CA2830660A1 (pt)
GB (1) GB2491006A (pt)
IL (1) IL228737B (pt)
MX (1) MX353816B (pt)
RU (1) RU2650784C2 (pt)
WO (1) WO2012150319A1 (pt)
ZA (1) ZA201308255B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
RU2607374C2 (ru) * 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
SG10201505218YA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Factor ix polypeptides and methods of use thereof
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
US20140128326A1 (en) * 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
EP3044232A1 (en) * 2013-09-13 2016-07-20 Novozymes Biopharma DK A/S Albumin variants
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
TW202311292A (zh) 2015-04-17 2023-03-16 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
MX2018001825A (es) * 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
WO2017112847A1 (en) 2015-12-22 2017-06-29 Albumedix A/S Improved protein expression strains
MA43571A (fr) 2015-12-23 2018-11-14 Biogen Ma Inc Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US11110122B2 (en) 2016-06-03 2021-09-07 New York University Methods and reagents for modulating macrophage phenotype
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018096396A1 (en) * 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
AU2017366674A1 (en) 2016-12-02 2019-06-20 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
BR112019012538A2 (pt) 2016-12-21 2019-11-12 Prometic Pharma Smt Ltd métodos e composições para prevenir ou minimizar a transição epitelial-mesenquimal
CN111032871A (zh) 2017-06-20 2020-04-17 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
DK3641800T3 (da) 2017-06-22 2024-01-02 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
JP7079171B2 (ja) 2017-08-03 2022-06-01 アムジエン・インコーポレーテツド インターロイキン－２１ムテイン及び治療方法
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN109553684A (zh) * 2017-09-25 2019-04-02 中国科学院过程工程研究所 一种纳米载体蛋白及其制备方法和应用
EP3697812A4 (en) * 2017-10-18 2021-09-22 CSL Limited HUMAN SERIAL ALBUMIN VARIANTS AND THEIR USES
JOP20200172A1 (ar) 2018-01-12 2020-07-12 Amgen Inc الأجسام المضادة لـ pd-1 وطرق العلاج
AR114541A1 (es) 2018-08-03 2020-09-16 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
CA3117409A1 (en) 2018-10-29 2020-05-07 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
PE20220401A1 (es) 2019-09-06 2022-03-22 Novartis Ag Proteinas de fusion terapeuticas
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4117722A1 (en) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
CA3199931A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Polypeptide constructs binding to cd3
TW202233678A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增強的剪切特徵的多肽
WO2022103781A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
WO2024025958A1 (en) * 2022-07-27 2024-02-01 Terraferma Foods, Inc. Compositions and methods for producing protein
WO2024089258A1 (en) 2022-10-28 2024-05-02 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613030B2 (en) 1987-04-09 1991-07-25 Novozymes Delta Limited Yeast vector
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6274305B1 (en) * 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
AU761591B2 (en) 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
WO2001079442A2 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
AU2003244516A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
DE602004017290D1 (de) 2003-02-17 2008-12-04 Novozymes Biopharma Uk Ltd Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
JP4492156B2 (ja) 2004-03-03 2010-06-30 ニプロ株式会社 血清アルブミンドメインを含む蛋白質
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
EP2169067A1 (en) 2004-12-22 2010-03-31 Novozymes A/S Recombinant production of serum albumin
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
AU2007274035A1 (en) 2006-07-13 2008-01-17 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
CN104193815A (zh) * 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2201036A1 (en) 2007-08-08 2010-06-30 Novozymes Biopharma DK A/S Transferrin variants and conjugates
AU2009234253C1 (en) * 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102307905B (zh) 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
JP5936112B2 (ja) * 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
CN102458442B (zh) 2009-04-08 2016-06-29 加利福尼亚大学董事会 具有受控血清药代动力学的人蛋白支架
WO2010138814A2 (en) 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions
AR077764A1 (es) 2009-07-20 2011-09-21 Univ Nat Cheng Kung Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
RU2607374C2 (ru) * 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
WO2011054148A1 (zh) 2009-11-06 2011-05-12 华为技术有限公司 一种资源配置方法和装置
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
EP2635598A1 (en) * 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants

Also Published As

Publication number Publication date
KR20140027307A (ko) 2014-03-06
US20120322739A1 (en) 2012-12-20
RU2650784C2 (ru) 2018-04-17
CN110272484A (zh) 2019-09-24
GB201207836D0 (en) 2012-06-20
US8822417B2 (en) 2014-09-02
JP6430828B2 (ja) 2018-11-28
GB2491006A (en) 2012-11-21
US20200102368A1 (en) 2020-04-02
WO2012150319A1 (en) 2012-11-08
EP2705051A1 (en) 2014-03-12
MX353816B (es) 2018-01-30
JP2014515614A (ja) 2014-07-03
US20140315816A1 (en) 2014-10-23
RU2013153816A (ru) 2015-06-10
CN104011072B (zh) 2018-10-12
AU2017225014A1 (en) 2017-09-28
CN104011072A (zh) 2014-08-27
IL228737B (en) 2019-03-31
CA2830660A1 (en) 2012-11-08
IL228737A0 (en) 2013-12-31
MX2013012358A (es) 2014-04-25
AU2012251583B2 (en) 2017-06-08
AU2012251583A1 (en) 2013-10-10
ZA201308255B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
BR112013028536A2 (pt) variantes de albumina
CY1119577T1 (el) Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
GB2488077A (en) Albumin variants
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
MX2015005495A (es) Formulaciones de proteina de inmunoglobulina del dominio variable dual estable.
UY34017A (es) Proteínas de fusión y vacunas de combinación
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
HN2013000125S1 (es) Diseño de botella de marinero
UY4210Q (es) Silla
MX368288B (es) Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
CL2016000219A1 (es) Proteinas de fusión terapéutica.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
BR112016024419A2 (pt) vacina profilática contra a síndrome da queda de postura (eds)
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
PH12015501854A1 (en) Factor ix polypeptide formulations
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
UY34312A (es) Compuesto de benzotiazolona
BR112016005972A2 (pt) plataforma semisubmersível equipada com um sistema de amplificação angular
CY1120748T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir
BR112016014615A2 (pt) Um pó de carbono condutivo, um método para a manufaturação do mesmo e utilização do mesmo
CL2012001192S1 (es) Botella.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ALBUMEDIX A/S (DK)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B25A Requested transfer of rights approved

Owner name: ALBUMEDIX LTD (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements